The Food and Drug Administration (FDA) published its analysis of the pill ahead of a public meeting scheduled for next week, in which academics and other experts will evaluate its safety and effectiveness.
The agency is not obliged to follow the advice of the group.
On the other hand, the study being carried out by MSD shows how the risk of hospitalization and death is reduced by almost half from the coronavirus. In fact, a team of independent experts who have overseen the trial recommended that it be stopped early due to positive results from the trial, the Washington Post reports.
Based on the data it manages, molnupiravir is likely effective against known variants of the coronavirus, including the dominant and highly transmissible Delta. If so, we would be facing the first effective antiviral pill against the disease that was born in Wuhan, China.
This targets viral polymerase, an enzyme necessary for the virus to make copies of itself. It is designed to work by introducing errors into the genetic code of the virus. The data shows that the drug is most effective when given in the early stages of infection, according to MSD.
The US drugmaker tested its antiviral on nasal swab samples taken from participants in the drug’s early trials. Delta was not in wide circulation at the time of those trials, but molnupiravir was tested against laboratory samples of the variant that is behind the latest spike in Covid-19 hospitalizations and deaths.
Source From: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
